<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>It has been reported that the induction of cellular senescence through p53 activation is an effective strategy in <z:mp ids='MP_0010537'>tumor regression</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Unfortunately, however, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> including adult T-cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> (ATL) have disadvantages such as p53 mutations and a lack of p16(INK4a) and/or p14(ARF) </plain></SENT>
<SENT sid="2" pm="."><plain>In this study we characterized <z:chebi fb="0" ids="46741">Nutlin</z:chebi>-3a-induced cell <z:hpo ids='HP_0011420'>death</z:hpo> in 16 <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines </plain></SENT>
<SENT sid="3" pm="."><plain>Eight cell lines, including six ATL-related cell lines, had <z:mp ids='MP_0002169'>wild-type</z:mp> p53 and <z:chebi fb="0" ids="46741">Nutlin</z:chebi>-3a-activated p53, and the cell lines underwent <z:mpath ids='MPATH_3'>apoptosis</z:mpath> or cell-cycle arrest, whereas eight cell lines with mutated p53 were resistant </plain></SENT>
<SENT sid="4" pm="."><plain>Interestingly, senescence-associated-beta-galactosidase (SA-beta-<z:chebi fb="125" ids="28260">gal</z:chebi>) staining revealed that only ATL-related cell lines with <z:mp ids='MP_0002169'>wild-type</z:mp> p53 showed cellular senescence, although they lack both p16(INK4a) and p14(ARF) </plain></SENT>
<SENT sid="5" pm="."><plain>These results indicate that cellular senescence is an important event in p53-dependent cell <z:hpo ids='HP_0011420'>death</z:hpo> in ATL cells and is inducible without p16(INK4a) and p14(ARF) </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, knockdown of Tp53-induced glycolysis and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> regulator (TIGAR), a novel target gene of p53, by small interfering <z:chebi fb="40" ids="33697">RNA</z:chebi>(siRNA) indicated its important role in the induction of cellular senescence </plain></SENT>
<SENT sid="7" pm="."><plain>As many patients with ATL carry <z:mp ids='MP_0002169'>wild-type</z:mp> p53, our study suggests that p53 activation by <z:chebi fb="0" ids="46741">Nutlin</z:chebi>-3a is a promising strategy in ATL </plain></SENT>
<SENT sid="8" pm="."><plain>We also found synergism with a combination of <z:chebi fb="0" ids="46741">Nutlin</z:chebi>-3a and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-related <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-inducing ligand (TRAIL), suggesting the application of <z:chebi fb="0" ids="46741">Nutlin</z:chebi>-3a-based therapy to be broader than expected </plain></SENT>
</text></document>